LifeMD, Inc. (LFMD)

In April 2025, LifeMD announced plans to expand affordable cash-pay access for weight loss drugs and extended insurance acceptance to Medicare beneficiaries. On May 6, 2025, the company touted a strong first quarter and raised its full-year guidance. On June 23, 2025, LifeMD declared a quarterly cash dividend for holders of its Series A Cumulative Perpetual Preferred Stock. In June and August 2025, executives and the CEO sold shares. On August 5, 2025, LifeMD reported its second-quarter 2025 financial results and significantly cut its full-year revenue guidance for 2025. On August 6, 2025, LifeMD's stock plummeted approximately 44.8%. In October 2025, multiple law firms initiated class-action lawsuits against LifeMD, alleging false and/or misleading statements and failure to disclose overstating the company's competitive position.

While there is some indication of seasonality in LifeMD's stock performance, specific details regarding the seasonality of demand for LifeMD's products and services are not explicitly provided. General market conditions can influence demand for telehealth services, and a decrease in disposable income might lead consumers to reduce discretionary healthcare spending. The company has experienced increasing demand for remote medical care and weight management treatments.

LifeMD, Inc. is a direct-to-patient telehealth company based in New York, NY, operating within the Healthcare sector and Health Information Services industry, aiming to provide patient-centric healthcare by connecting consumers to healthcare professionals across the United States. LifeMD offers a portfolio of direct-to-patient products and services, combining virtual medical treatment with prescription medications and over-the-counter products. Its major products and segments include virtual primary care services, RexMD, and weight management programs, notably offering Ozempic through a collaboration with Novo Nordisk. The company also operates ShapiroMD and a non-core segment called WorkSimpli. LifeMD emphasizes a vertically integrated approach, controlling its technology platform, a nationwide network of doctors, and its own pharmacy services.

LifeMD, Inc. primarily operates in the United States and is headquartered in New York, NY.

LifeMD's brand reputation has been negatively impacted due to the Q2 2025 earnings report, the downward revision of revenue guidance, and the subsequent stock drop. Multiple securities class-action lawsuits alleging misleading disclosures regarding its competitive position, customer acquisition costs in RexMD, and refund rates in weight management have further damaged its reputation. A parallel data privacy settlement involving the sharing of patient health information with third-party platforms has amplified concerns about governance.

LifeMD, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Morgan Stanley, D. E. Shaw & Co., Inc., Nuveen, LLC, State Street Corp, Renaissance Technologies Llc, UBS Group AG, and Connor, Clark & Lunn Investment Management Ltd. Justin Schreiber owns the most shares among individuals, and the general public also holds a substantial stake.